BRIDGEBIO PHARMA INC's ticker is and the CUSIP is 10806XAB8. A total of 41 filers reported holding BRIDGEBIO PHARMA INC in Q2 2024. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $15,062,016 | -6.2% | 15,226,000 | +2.0% | 0.00% | 0.0% |
| Q1 2024 | $16,065,370 | -22.6% | 14,933,000 | -13.1% | 0.00% | -20.0% |
| Q4 2023 | $20,757,740 | +15.8% | 17,181,000 | -7.8% | 0.01% | 0.0% |
| Q3 2023 | $17,927,952 | +43.2% | 18,640,000 | +16.8% | 0.01% | +66.7% |
| Q2 2023 | $12,516,351 | +21.7% | 15,957,000 | +16.0% | 0.00% | 0.0% |
| Q1 2023 | $10,282,944 | +112.8% | 13,757,000 | +13.2% | 0.00% | +200.0% |
| Q4 2022 | $4,832,408 | -32.4% | 12,157,000 | 0.0% | 0.00% | -50.0% |
| Q3 2022 | $7,149,000 | +30.7% | 12,157,000 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $5,470,000 | -29.3% | 12,157,000 | -7.6% | 0.00% | 0.0% |
| Q1 2022 | $7,733,000 | -27.6% | 13,157,000 | -10.2% | 0.00% | -33.3% |
| Q4 2021 | $10,681,000 | +7.9% | 14,656,000 | +104.8% | 0.00% | +50.0% |
| Q3 2021 | $9,897,000 | -60.1% | 7,156,000 | -52.8% | 0.00% | -60.0% |
| Q2 2021 | $24,785,000 | +68.8% | 15,156,000 | +71.4% | 0.01% | +66.7% |
| Q1 2021 | $14,685,000 | – | 8,845,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BRAIDWELL LP | 143,338,000 | $106,213,458 | 3.50% |
| ARISTEIA CAPITAL, L.L.C. | 167,448,000 | $124,078,968 | 2.91% |
| Affinity Asset Advisors, LLC | 10,000,000 | $7,410,000 | 2.44% |
| CONTRARIAN CAPITAL MANAGEMENT, L.L.C. | 8,500,000 | $6,256,000 | 1.62% |
| TFG Asset Management GP Ltd | 10,000,000 | $7,473,611 | 1.00% |
| Context Capital Management, LLC | 14,785 | $10,956 | 0.92% |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 30,329,000 | $22,670 | 0.83% |
| Weiss Asset Management LP | 7,500,000 | $5,582,792 | 0.36% |
| CSS LLC/IL | 6,600,000 | $4,887,815 | 0.32% |
| MACKAY SHIELDS LLC | 14,404,000 | $10,673,364 | 0.29% |